Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

The prognostic value of pfetin: a validation study in gastrointestinal stromal tumors using a commercially available antibody.

Kubota D, Mukaihara K, Yoshida A, Suehara Y, Saito T, Okubo T, Gotoh M, Orita H, Tsuda H, Kaneko K, Kawai A, Kondo T, Sato K, Yao T.

Jpn J Clin Oncol. 2013 Jun;43(6):669-75. doi: 10.1093/jjco/hyt057. Epub 2013 Apr 25.

PMID:
23619989
2.

Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities.

Kikuta K, Gotoh M, Kanda T, Tochigi N, Shimoda T, Hasegawa T, Katai H, Shimada Y, Suehara Y, Kawai A, Hirohashi S, Kondo T.

Jpn J Clin Oncol. 2010 Jan;40(1):60-72. doi: 10.1093/jjco/hyp125. Epub 2009 Oct 7.

PMID:
19815537
3.

Validation study on pfetin and ATP-dependent RNA helicase DDX39 as prognostic biomarkers in gastrointestinal stromal tumour.

Kubota D, Okubo T, Saito T, Suehara Y, Yoshida A, Kikuta K, Tsuda H, Katai H, Shimada Y, Kaneko K, Kawai A, Kondo T.

Jpn J Clin Oncol. 2012 Aug;42(8):730-41. doi: 10.1093/jjco/hys092. Epub 2012 Jun 21.

PMID:
22723667
4.

Pfetin as a prognostic biomarker for gastrointestinal stromal tumor: validation study in multiple clinical facilities.

Kubota D, Orita H, Yoshida A, Gotoh M, Kanda T, Tsuda H, Hasegawa T, Katai H, Shimada Y, Kaneko K, Kawai A, Kondo T.

Jpn J Clin Oncol. 2011 Oct;41(10):1194-202. doi: 10.1093/jjco/hyr121. Epub 2011 Sep 8.

PMID:
21903705
5.

Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics.

Suehara Y, Kondo T, Seki K, Shibata T, Fujii K, Gotoh M, Hasegawa T, Shimada Y, Sasako M, Shimoda T, Kurosawa H, Beppu Y, Kawai A, Hirohashi S.

Clin Cancer Res. 2008 Mar 15;14(6):1707-17. doi: 10.1158/1078-0432.CCR-07-1478.

6.

Pfetin as a risk factor of recurrence in gastrointestinal stromal tumors.

Orita H, Ito T, Kushida T, Sakurada M, Maekawa H, Wada R, Suehara Y, Kubota D, Sato K.

Biomed Res Int. 2014;2014:651935. doi: 10.1155/2014/651935. Epub 2014 May 26.

7.

[Biomarker development by cancer proteomics].

Kondo T.

Nihon Rinsho. 2012 May;70(5):754-8. Review. Japanese.

PMID:
22619997
8.

Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors.

Li CF, Huang WW, Wu JM, Yu SC, Hu TH, Uen YH, Tian YF, Lin CN, Lu D, Fang FM, Huang HY.

Clin Cancer Res. 2008 Dec 1;14(23):7822-31. doi: 10.1158/1078-0432.CCR-08-1369.

9.

Survival and prognostic factors analysis in surgically resected gastrointestinal stromal tumor patients.

Song Z, Wang JL, Pan YL, Tao DY, Gan MF, Huang KE.

Hepatogastroenterology. 2009 Jan-Feb;56(89):149-53.

PMID:
19453047
10.

Prognostic analysis of patients with gastrointestinal stromal tumors: a single unit experience with surgical treatment of primary disease.

Cao H, Zhang Y, Wang M, Shen DP, Sheng ZY, Ni XZ, Wu ZY, Liu Q, Shen YY, Song YY.

Chin Med J (Engl). 2010 Jan 20;123(2):131-6.

PMID:
20137358
11.

Proteomic approach toward personalized sarcoma treatment: lessons from prognostic biomarker discovery in gastrointestinal stromal tumor.

Kondo T, Suehara Y, Kikuta K, Kubota D, Tajima T, Mukaihara K, Ichikawa H, Kawai A.

Proteomics Clin Appl. 2013 Jan;7(1-2):70-8. doi: 10.1002/prca.201200085. Review.

PMID:
23281253
12.

The abnormalities in the p53/p21WAF1 pathway have a significant role in the pathogenesis and progression of gastrointestinal stromal tumors.

Chou YP, Lin JW, Wang CC, Chiu YC, Huang CC, Chuah SK, Tai MH, Yi LN, Lee CM, Changchien CS, Hu TH.

Oncol Rep. 2008 Jan;19(1):49-56.

PMID:
18097575
13.
14.

Characteristics of KIT-negative gastrointestinal stromal tumours and diagnostic utility of protein kinase C theta immunostaining.

Lee HE, Kim MA, Lee HS, Lee BL, Kim WH.

J Clin Pathol. 2008 Jun;61(6):722-9. doi: 10.1136/jcp.2007.052225. Epub 2008 Apr 1.

PMID:
18381383
15.

Expression of p16INK4A in gastrointestinal stromal tumours (GISTs): two different forms exist that independently correlate with poor prognosis.

Haller F, Agaimy A, Cameron S, Beyer M, Gunawan B, Happel N, Langer C, Ramadori G, von Heydebreck A, Füzesi L.

Histopathology. 2010 Feb;56(3):305-18. doi: 10.1111/j.1365-2559.2010.03478.x.

PMID:
20459531
16.

[Gastrointestinal stromal tumors (GIST): factors predictive of survival after R0-cytoreduction].

Sánchez Hidalgo JM, Muñoz Casares FC, Rufian Peña S, Naranjo Torres A, Ciria Bru R, Briceño Delgado J, López Cillero P.

Rev Esp Enferm Dig. 2007 Dec;99(12):703-8. Spanish.

17.

Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate.

Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, Raymond AK, Benjamin RS, Zhang W, Trent JC.

Cancer. 2006 Apr 1;106(7):1617-23.

18.

Ezrin overexpression in gastrointestinal stromal tumors: an independent adverse prognosticator associated with the non-gastric location.

Wei YC, Li CF, Yu SC, Chou FF, Fang FM, Eng HL, Uen YH, Tian YF, Wu JM, Li SH, Huang WW, Li WM, Huang HY.

Mod Pathol. 2009 Oct;22(10):1351-60. doi: 10.1038/modpathol.2009.107. Epub 2009 Jul 31.

19.

Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review.

Cirocchi R, Farinella E, La Mura F, Cavaliere D, Avenia N, Verdecchia GM, Giustozzi G, Noya G, Sciannameo F.

Tumori. 2010 May-Jun;96(3):392-9. Review.

20.

Involvement of focal adhesion kinase in the progression and prognosis of gastrointestinal stromal tumors.

Kamo N, Naomoto Y, Shirakawa Y, Yamatsuji T, Hirota S, Fujiwara Y, Noma K, Sakurama K, Takaoka M, Nagatsuka H, Gunduz M, Matsuoka J, Tanaka N.

Hum Pathol. 2009 Nov;40(11):1643-9. doi: 10.1016/j.humpath.2009.05.004. Epub 2009 Aug 19.

PMID:
19695682

Supplemental Content

Support Center